BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33296518)

  • 1. Review article: Elobixibat: a novel treatment for chronic constipation.
    Khanna L; Camilleri M
    Aliment Pharmacol Ther; 2021 Jan; 53(2):234-242. PubMed ID: 33296518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elobixibat for the treatment of constipation.
    Chedid V; Vijayvargiya P; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):951-960. PubMed ID: 30204504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
    Misawa N; Higurashi T; Takatsu T; Iwaki M; Kobayashi T; Yoshihara T; Ashikari K; Kessoku T; Fuyuki A; Matsuura T; Ohkubo H; Usuda H; Wada K; Naritaka N; Takei H; Nittono H; Matsumoto M; Honda A; Nakajima A; Camilleri M
    Aliment Pharmacol Ther; 2020 Sep; 52(5):821-828. PubMed ID: 32687674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elobixibat for the treatment of constipation.
    Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial.
    Nakajima A; Seki M; Taniguchi S
    J Gastroenterol; 2018 Apr; 53(4):525-534. PubMed ID: 28840422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation.
    Miner PB
    Expert Opin Pharmacother; 2018 Aug; 19(12):1381-1388. PubMed ID: 30129377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
    Nakajima A; Ishizaki S; Matsuda K; Kurosu S; Taniguchi S; Gillberg PG; Mattsson JP; Hasunuma T; Camilleri M
    J Gastroenterol Hepatol; 2022 May; 37(5):883-890. PubMed ID: 35168298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
    Nakajima A; Taniguchi S; Kurosu S; Gillberg PG; Mattsson JP; Camilleri M
    Neurogastroenterol Motil; 2019 May; 31(5):e13571. PubMed ID: 30793431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
    Ikeda N; Taniguchi S; Seki M
    Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
    Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
    Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Elobixibat in Parkinson's Disease with Chronic Constipation: CONST-PD Study.
    Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Nakamura R; Tsunemi T; Ogawa T; Eguchi H; Daida K; Kurita N; Ueno SI; Fukae J; Sako W; Shiina K; Nakajima S; Oji Y; Wakamori R; Saiki S; Nishioka K; Okuzumi A; Taniguchi D; Takeshige-Amano H; Fuse A; Nakajima A; Kano M; Kamo H; Yamashita Y; Shindo A; Yanagisawa N; Hattori N
    Mov Disord Clin Pract; 2024 Apr; 11(4):352-362. PubMed ID: 38264844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study.
    Kamei D; Kamei Y; Nagano M; Mineshima M; Nitta K; Tsuchiya K
    BMC Gastroenterol; 2020 Jan; 20(1):26. PubMed ID: 32005162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
    Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
    BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake.
    Ozaki A; Kessoku T; Kasai Y; Takeda Y; Okubo N; Iwaki M; Kobayashi T; Yoshihara T; Honda Y; Fuyuki A; Higurashi T; Ishiki H; Taguri M; Oyamada S; Kobayashi N; Nakajima A; Ichikawa Y
    Oncologist; 2021 Oct; 26(10):e1862-e1869. PubMed ID: 34180099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.
    Manabe N; Umeyama M; Ishizaki S; Ota T; Kuratani S; Katsumata R; Fujita M; Haruma K; Camilleri M
    BMJ Open Gastroenterol; 2023 Nov; 10(1):. PubMed ID: 37993269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).
    Hatano T; Oyama G; Shimo Y; Ogaki K; Nishikawa N; Fukae J; Nakamura R; Kurita N; Tsunemi T; Oji Y; Saiki S; Nishioka K; Takeshige-Amano H; Taniguchi D; Ogawa T; Kamo H; Eguchi H; Fuse A; Nakajima A; Kano M; Nakajima S; Yanagisawa N; Hattori N
    BMJ Open; 2022 Feb; 12(2):e054129. PubMed ID: 35149566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs.
    Taniguchi S; Yano T; Imaizumi M; Manabe N
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13448. PubMed ID: 30129138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.
    Mosińska P; Fichna J; Storr M
    World J Gastroenterol; 2015 Jun; 21(24):7436-42. PubMed ID: 26139989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pharmacological treatment options for chronic constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.